Literature DB >> 11095593

Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.

J Venhorst1, R C Onderwater, J H Meerman, J N Commandeur, N P Vermeulen.   

Abstract

A series of six structural analogs of 7-methoxy-4-(aminomethyl)-coumarin (MAMC), a recently developed high-throughput substrate of P450 2D6 (CYP2D6), was synthesized to investigate the influence of N-substitution on the metabolism by cytochrome P450s, as well as on P450 selectivity. The analogs were obtained by introducing alkyl substituents at the amino group of MAMC and by replacing this moiety with a pyridine group. Competition experiments using heterologously expressed CYP2D6 demonstrated that the introduction and elongation of alkyl substituents strongly decreased the IC(50) values toward dextromethorphan O-demethylation. Metabolism studies showed that the regioselectivity of metabolism was unaffected by the varying N substituents, as only O-dealkylation of the analogs and no N-dealkylation was observed. In excellent agreement with the competition experiments, metabolism studies also showed that elongation of the alkyl chain dramatically increased the affinity of the compounds toward CYP2D6, as indicated by an up to 100-fold decrease in K(m) values. The V(max) values displayed a much less pronounced decrease with an increasing N-alkyl chain, resulting in as much as a 30-fold increase in the V(max)/K(m) value. Interestingly, due to the higher fluorescent yield of the N-alkyl metabolites compared with the metabolite of MAMC, O-dealkylation of N-methyl MAMC by CYP2D6 can be measured with a more than 3-fold higher sensitivity. Studies on P450 selectivity showed that only CYP1A2 and CYP2D6 contribute to the O-dealkylation of the N-alkyl analogs in both heterologously expressed P450s and human liver microsomes. In sharp contrast to CYP2D6, N-alkylation of MAMC did not significantly affect the K(m) values of O-dealkylation by CYP1A2, but it did result in higher V(max) values. Finally, CYP1A2 also N-dealkylated the analogs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095593

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

2.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

3.  Evaluation of alpha-cyano ethers as fluorescent substrates for assay of cytochrome P450 enzyme activity.

Authors:  Kyung-Don Kang; Paul D Jones; Huazhang Huang; Rong Zhang; Lyudmila A Mostovich; Craig E Wheelock; Takaho Watanabe; Lyudmila F Gulyaeva; Bruce D Hammock
Journal:  Anal Biochem       Date:  2005-09-15       Impact factor: 3.365

4.  A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes.

Authors:  Lei Feng; Xiangge Tian; Dahong Yao; Zhenlong Yu; Xiaokui Huo; Zhenhao Tian; Jing Ning; Jingnan Cui; Tony D James; Xiaochi Ma
Journal:  Acta Pharm Sin B       Date:  2021-11-25       Impact factor: 14.903

5.  Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.

Authors:  Charleen G Don; Martin Smieško
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

Review 6.  "Commandeuring" Xenobiotic Metabolism: Advances in Understanding Xenobiotic Metabolism.

Authors:  Barbara M A van Vugt-Lussenburg; Liliana Capinha; Jelle Reinen; Martijn Rooseboom; Michel Kranendonk; Rob C A Onderwater; Paul Jennings
Journal:  Chem Res Toxicol       Date:  2022-06-29       Impact factor: 3.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.